Data de publicação: 03/11/2021 - 11:26
A new study published in Nature Communications last Thursday (28/11) shows that two doses of the AstraZeneca vaccine, produced in Brazil by Fiocruz, provide high protection against the Gamma variant in people above 60 years old. Based on São Paulo, the research shows that the second dose increases protection against death by about 30% when compared to the first dose, reaching an effectivity of 93.6%. Carried out by 20 researchers in...
Notícias
Data de publicação: 03/11/2021 - 09:39
Ten years after its signing, the Rio Political Declaration on Social Determinants of Health is more relevant than ever, as shown by the impacts of the COVID-19 pandemic in the world. To celebrate the document’s tenth anniversary and evaluate the approaches adopted since, two webinars held last Thursday (21 October) brought together many actors that were crucial for the negotiations that culminated in the declaration and for the quest for...
Notícias
Data de publicação: 29/10/2021 - 10:09
The team of the Viral Vaccines Laboratory of the National Institute for Quality Control in Health (INCQS/Fiocruz), which works with immunobiological drugs against rabies (LVV-Raiva), is participating in the second phase of an international study to replace potency assays in anti-rabies vaccines, traditionally made using mice for over 50 years.
Under code BSP148 and funded by the European Directorate for the Quality of Medicines and...
Notícias
Data de publicação: 27/10/2021 - 12:27
Production of the Fiocruz Active Pharmaceutical Ingredient (API) for COVID-19 vaccines is ongoing and is now moving on to a new and important phase of the process. Two pre-validation batches of the product manufactured by Fiocruz have been approved in all in-house quality tests and are now on their way to an external quality control at USA laboratories. At these labs, the samples will go through a complex testing process that involves 14 tests...
Notícias
Data de publicação: 27/10/2021 - 12:01
When Fiocruz joined the small summit of guest countries of the Global Sustainable Technology and Innovation Community (G-STIC) in 2018, the world still did not know Sars-CoV-2. Now, while the world population takes the vaccine for COVID-19, the fifth edition of the annual conference (the fourth with the participation of the Foundation), bets on a hybrid participation model from October 24th to 26th. The agenda includes both virtual and on-site...
Notícias
Data de publicação: 22/10/2021 - 09:48
Would it be possible to establish a new food model without the large producers' participation? Finding this answer is an ongoing global challenge and resounded in the seminar Food security, health and pandemics in United Nations events, organized by the Fiocruz Global Health Center (CRIS/Fiocruz). Divergent analyses and opinions revealed behind the scenes of international decisions on hunger programs and inspired empathy in provocative,...
Notícias
Data de publicação: 21/10/2021 - 13:21
Este relatório apresenta resultados preliminares da pesquisa “Covid-19, risco, impacto e resposta de gênero”, desenvolvida no Brasil pela Fiocruz e instituições parceiras1. Diversos temas relacionados aos impactos da pandemia da Covid-19 na vida das mulheres são contemplados pela pesquisa, mas este relatório concentra-se no tema da insegurança alimentar. São apresentados relatos...
Documento/Arquivo
Data de publicação: 20/10/2021 - 10:49
A cooperation that dates back to the beginning of the last century and that has been renovated and expanded over the decades was celebrated last Thursday (October 14th), with the visit of Portugal’s assistant secretary of Health, António Lacerda Sales, to Fiocruz. Accompanied by the Secretary of State of the Portuguese Communities, Berta Nunes, and by ambassador Luís Faro Ramos, among other members of the delegation, Sales...
Notícias
Data de publicação: 18/10/2021 - 16:03
After a one-year break due to the restrictions caused by the COVID-19 pandemic, the Fiocruz in Antarctica (Fioantar) project resumed its scientific excursions into the continent with a new departure this Wednesday morning (10/13). After a week of quarantine with actions to fight COVID-19, including diagnostic tests before and during the period, the Ary Rongel oceanographic support ship set sail to the Comandante Ferraz Antarctic Station carrying...
Notícias
Data de publicação: 18/10/2021 - 12:05
A study led by the Center for the Integration of Data and Knowledge on Health (Cidacs/Fiocruz Bahia) suggests that C-sections may be associated with a higher risk of infant mortality, with the exception of cases in which a medical indication is clear on this procedure, which is popularly known as “cesarean” in Brazil.
Photo: Courtesy
Using data collected and provided by the Ministry of Health on more than 17 million...
Notícias
Data de publicação: 16/10/2021 - 17:55
Sociologist and Fiocruz president, Nísia Trindade Lima, presented last Friday (October 8th) the conference Pandemic and Social Inequalities: Challenges for Global Health. The event was part of the Global Health Colloquium Series, a biannual series of lectures by Princeton University's Program in Global Health. Nísia thanked the university and Brazil Lab for the invitation, a hub that connects researchers and professors...
Notícias
Data de publicação: 13/10/2021 - 15:53
Fiocruz will be part, starting next week, of a Phase 3 international multicenter study with the drug Molnupiravir, manufactured by the pharmaceutical company MSD. The goal is to verify its efficiency to prevent the COVID-19 spread and transmission among people exposed to the Sars-CoV-2 virus. The study will occur simultaneously in seven centers in Brazil, two of which are under the Fiocruz responsibility: Mato Grosso do Sul and Rio de Janeiro....
Notícias
Data de publicação: 13/10/2021 - 13:47
On Thursday (September, 30th), the project for the installation of the Pharmaceutical Plant in Maputo, Mozambique capital, was concluded. The announcement was made in a joint statement by the Brazil and Mozambique governments and is the result of the technology transfer mission and partnership with the Institute of Technology in Medicines (Farmanguinhos/Fiocruz).
"We are finishing this important project with the merit of having left the...
Notícias
Data de publicação: 13/10/2021 - 11:13
The ambassador of Botswana to Brazil, Tebogo Montshome, visited Fiocruz last Thursday (October 7th). She decided to get to know the Foundation while visiting Rio de Janeiro to identify areas of possible cooperation between her country and the institution. Greeted by the Vice-President of Production and Innovation in Health, Marco Krieger, Montshome was particularly interested in staff training, research and production of drugs and vaccines....
Notícias
Data de publicação: 08/10/2021 - 17:05
With Fiocruz among the signatories, it was launched this Wednesday (October 6), the São Paulo Declaration on Planetary Health, an initiative of Planetary Health Alliance and the University of São Paulo, in partnership with the United Nations Development Programme (UNDP). The declaration is considered the first document of the global planetary health community to describe the actions needed to achieve what it calls "the great...
Notícias
Data de publicação: 07/10/2021 - 17:11
A new study by Fiocruz on the effectiveness of vaccination in Brazil shows that the population has benefitted from the vaccination plan against the Sars-CoV-2 in the prevention of severe cases and deaths by Covid-19, although effectiveness varies between age groups. The analysis, which also included subjects vaccinated with the first dose of the Pfizer shot, was carried out between January 17 and July 19 this year, a total of six months, in...
Notícias
Data de publicação: 07/10/2021 - 14:50
In the first decades of the twentieth century, the American multinational United Fruit Company, prominent in the production and sale of tropical fruits, found a way to deal with malnutrition among its workers in Costa Rica: it imported canned and processed foods from the United States. At the same time, the solution to high infant mortality in the banana plantation zone was the introduction of an artificial food developed by Nestlé. Years...
Notícias
Data de publicação: 07/10/2021 - 11:26
The Institute of Drug Technology (Farmanguinhos/Fiocruz) is closer to starting Pediatric Praziquantel production, indicated for schistosomiasis, a parasitic disease that affects about 200 million people worldwide, half of whom are children. Result of the International Pediatric Praziquantel Consortium, the drug is in the clinical trials last phase. Pilot batches are expected to be produced in March 2022 and the product available in 2024...
Notícias
Data de publicação: 05/10/2021 - 17:22
Large-scale deforestation of the Amazon forest associated with climate change will increase the risk of exposure to extreme heat. Such levels of heat, which will be physiologically intolerable for the human body, will profoundly affect regions inhabited by highly vulnerable populations, according to a study published by researchers Beatriz Alves de Oliveira, of Fiocruz; Marcus Bottino and Paulo Nobre, both of the National Institute of Space...
Notícias
Data de publicação: 05/10/2021 - 16:32
The Evandro Chagas National Institute of Infectious Diseases (INI/Fiocruz) is now open for enrollment, up to November 1, into the Fourth International Course on Immunohistochemistry, Molecular Pathology and Histopathology for the Diagnosis of Infectious Diseases. Coordinated by Rodrigo Caldas Menezes, Luiz Cláudio Ferreira and Leonardo Pereira Quintella, the training is aimed at healthcare professionals, especially those that work or...
Notícias
Data de publicação: 04/10/2021 - 10:54
The COVID-19 pandemic was one of the main subjects discussed at two meetings that drew the attention of the entire world and of the region last week. While chiefs of state and of government debated the effects of the disease at the 76th General Assembly of the United Nations, at the 59th Board of Directors and 73rd Session of the Regional Committee of the World Health Organization (WHO) for the Americas, organized by the Pan-American Health...
Notícias
Data de publicação: 30/09/2021 - 14:08
By means of its Immunobiological Technology Institute (Bio-Manguinhos), last Monday (September 27th) Fiocruz ended the production of the first batches called pre-validation batches of the national Active Pharmaceutical Ingredient (API) for the COVID-19 vaccine. The ingredient will now be submitted to quality control tests at the institution to then be sent to the final processing phase of the vaccine. The first pre-validation batch, which was...
Notícias
Data de publicação: 27/09/2021 - 18:04
Diseases that Brazilians are very familiar with, such as dengue fever, zika and chikungunya, are being directly affected by the pandemic, both with the transfer of human and material resources to the fight against COVID-19 and with possible undernotifications. But we can learn lessons from this experience, as shown by the 20th Advanced Seminaries on Global Health and Health Diplomacy of the Fiocruz Global Health Center (CRIS/Fiocruz), held last...
Notícias
Data de publicação: 24/09/2021 - 10:56
The Immunobiological Technology Institute (Bio-Manguinhos/Fiocruz) was selected last Tuesday (September 21st) by the World Health Organization (WHO) as a hub for the development and production of vaccines using messenger RNA in Latin America. This Foundation unit was chosen due to the promising advancements in the technological development of an mRNA vaccine against Covid-19, currently in a pre-clinical stage. The initiative used resources of...
Notícias
Data de publicação: 24/09/2021 - 10:24
As part of the preparations for the new Brazilian expedition to Antarctica, Fiocruz donated 3,000 rapid tests to detect Sars-Cov-2 antigens to the Navy. The kits, produced by the Institute of Technology in Immunobiologicals (Bio-Manguinhos/Fiocruz), will be used to test the entire crew on board, on the support flights, the team at the Comandante Ferraz Antarctic Station and the researchers who will be part of the new trip - including the...
Notícias
O conteúdo deste portal pode ser utilizado para todos os fins não comerciais, respeitados e reservados os direitos morais dos autores.
